EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Haemolytic uremic syndrome as a cause of chronic kidney disease stage 5 in children is in retreat: results from the Polish Registry of Kidney Replacement Therapy in children (2000–2023)

Ilona Zagożdżon, Maria Szczepańska, Jacek Rubik, Katarzyna Zachwieja, Anna Musielak, Monika Bratkowska, Irena Makulska, Katarzyna Niwińska, Beata Leszczyńska, Beata Bieniaś, Katarzyna Taranta-Janusz, Hanna Adamczyk-Kipigroch und 1 weitere

Pediatric Nephrology · 2025

DOI: 10.1007/s00467-024-06584-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Nephrology, 2025. Verfasst von Ilona Zagożdżon und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Nephrology and Hypertension, Medical University of Gdansk, Debinki 7, 80-211, Gdansk, Poland. ilona.zagozdzon@gumed.edu.pl. Hauptthemen laut MEDLINE: Hemolytic-Uremic Syndrome, Renal Replacement Therapy, Escherichia coli Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Haemolytic uremic syndrome (HUS) is a life-threatening disease with a historically poor prognosis in children receiving maintenance kidney replacement therapy (KRT). This study aimed to analyse the incidence and outcome of chronic kidney disease stage 5 (CKD5) due to Escherichia coli -HUS (STEC-HUS) and complement-mediated HUS (CM-HUS) in children, compared with controls with non-HUS CKD5 over the last 24 years.

Methods

The study included 1488 children undergoing KRT in Poland between 2000 and 2023. Thirty-nine patients with CM-HUS and 18 with STEC-HUS were identified and analysed for incidence, KRT modality and survival.

Results

The incidence rate of CKD5 was 0.09 cases/million age-related population (marp) for STEC-HUS and 0.23/marp for CM-HUS, while no new cases have been observed in recent years. CKD5 due to CM-HUS developed significantly earlier from initial HUS manifestation than in STEC-HUS (median 0.2 vs. 9.8 years). CM-HUS was associated with younger age at initiation of KRT compared to STEC-HUS and non-HUS controls (median 6.0 years vs. 10.9 and 10.9 years), with higher risk of death (Hazard Ratio 1.92, 95% confidence interval 0.9–4.13) and worse 5-year kidney graft survival at 77%, 93% and 90%, respectively ( p < 0.001).

Conclusions

In recent years, both CM-HUS and STEC-HUS have become increasingly rare causes of CKD5 in children. CKD5 due to CM-HUS in the eculizumab era and due to STEC-HUS after improving supportive treatment is exceptional. Children on KRT due to STEC-HUS had a significantly better survival, shorter waiting time for kidney transplantation and better kidney graft survival compared to the CM-HUS group. Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemolytic-Uremic SyndromeRenal Replacement TherapyEscherichia coli InfectionsHumansChildMaleFemalePolandRegistriesChild, PreschoolInfantAdolescentIncidenceKidney TransplantationShiga-Toxigenic Escherichia coli

Stichwörter der Autor:innen

ChildrenChronic kidney diseaseEpidemiologyHaemolytic uremic syndromeSurvival

Autor:innen und Institutionen

  • Department of Pediatrics, Nephrology and Hypertension, Medical University of Gdansk, Debinki 7, 80-211, Gdansk, Poland. ilona.zagozdzon@gumed.edu.pl.
  • Department and Clinic of Pediatrics, Nephrology and Endocrinology, Medical University of Silesia, Zabrze, Poland.
  • Department of Nephrology and Kidney Transplantation, The Childrens Memorial Health Institute, Warsaw, Poland.
  • Department of Pediatric Nephrology and Hypertension, Jagiellonian University Medical College, Krakow, Poland.
  • Department of Pediatric Cardiology and Nephrology, Poznan University of Medical Sciences, Poznan, Poland.
  • Department of Pediatrics, Immunology and Nephrology, Polish Mother's Memorial Hospital - Research Institute in Lodz, Lodz, Poland.

Zitieren

APA

Zagożdżon, I., Szczepańska, M., Rubik, J., Zachwieja, K., Musielak, A., Bratkowska, M., Makulska, I., Niwińska, K., Leszczyńska, B., Bieniaś, B., Taranta-Janusz, K., Adamczyk-Kipigroch, H., & Żurowska, A. (2025). Haemolytic uremic syndrome as a cause of chronic kidney disease stage 5 in children is in retreat: results from the Polish Registry of Kidney Replacement Therapy in children (2000–2023). Pediatric Nephrology. https://doi.org/10.1007/s00467-024-06584-2

Vancouver

Zagożdżon I, Szczepańska M, Rubik J, Zachwieja K, Musielak A, Bratkowska M, et al. Haemolytic uremic syndrome as a cause of chronic kidney disease stage 5 in children is in retreat: results from the Polish Registry of Kidney Replacement Therapy in children (2000–2023). Pediatric Nephrology. 2025. doi:10.1007/s00467-024-06584-2

BibTeX
@article{Zagodon2025,
  author = {Zagożdżon, Ilona and Szczepańska, Maria and Rubik, Jacek and Zachwieja, Katarzyna and Musielak, Anna and Bratkowska, Monika and Makulska, Irena and Niwińska, Katarzyna and Leszczyńska, Beata and Bieniaś, Beata and Taranta-Janusz, Katarzyna and Adamczyk-Kipigroch, Hanna and Żurowska, Aleksandra},
  title = {Haemolytic uremic syndrome as a cause of chronic kidney disease stage 5 in children is in retreat: results from the Polish Registry of Kidney Replacement Therapy in children (2000–2023)},
  journal = {Pediatric Nephrology},
  year = {2025},
  doi = {10.1007/s00467-024-06584-2}
}
Kostenlos starten →